lactic acid has been researched along with Carcinoma, Renal Cell in 22 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clear cell renal cell carcinoma (ccRCC) is the most common pathological subtype of kidney cancer." | 2.48 | Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. ( Burrell, RA; Dykema, K; Endesfelder, D; Gerlinger, M; Howell, M; Jiang, M; Kelly, G; Larkin, J; Martinez, P; Patard, JJ; Rioux-Leclercq, N; Santos, CR; Saunders, RE; Spencer-Dene, B; Stamp, G; Swanton, C; Vetter, M, 2012) |
| "Lactic acid was previously considered a waste product of glycolysis, and has now become a key metabolite for cancer development, maintenance and metastasis." | 1.72 | Lactic Acid Metabolism and Transporter Related Three Genes Predict the Prognosis of Patients with Clear Cell Renal Cell Carcinoma. ( Chen, S; Guo, T; Tang, H; Wang, T; Wang, X; Yuan, Z; Zhang, D; Zhang, J, 2022) |
| "Patients with high-risk non-metastatic renal cell carcinoma (RCC) are at risk of metastatic relapse following nephrectomy." | 1.72 | Cabozantinib-Loaded PLGA Nanoparticles: A Potential Adjuvant Strategy for Surgically Resected High-Risk Non-Metastatic Renal Cell Carcinoma. ( Choy, YB; Kim, CR; Kim, SN; Lee, HW; Park, CG; Park, DH; Park, W; Seo, HS; Seo, SI; Yeom, SY, 2022) |
| "Determining the aggressiveness of renal cell carcinoma (RCC) noninvasively is a critical part of the diagnostic workup for treating this disease that kills more than 15,000 people annually in the USA." | 1.62 | Modeling hyperpolarized lactate signal dynamics in cells, patient-derived tissue slice cultures and murine models. ( Ahamed, F; Kurhanewicz, J; Larson, P; Sriram, R; Van Criekinge, M; Wang, ZJ, 2021) |
| " At maximum dosage and time (15 μM and 96 h), Sorafenib-loaded PLGA and HMC-coated liposomes killed 88." | 1.42 | Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma. ( Arora, J; Boonkaew, B; Callaghan, C; Chava, S; Dash, S; He, J; John, VT; Lee, BR; Liu, J; Maddox, MM; Mandava, SH, 2015) |
| "In a renal cell carcinoma cell (RCC) line, bidirectional exchange was observed." | 1.42 | Dynamic UltraFast 2D EXchange SpectroscopY (UF-EXSY) of hyperpolarized substrates. ( Koelsch, B; Kurhanewicz, J; Larson, P; Leon Swisher, C; Santos, RD; Sriram, R; Sukumar, S; Vigneron, D; Wang, ZJ, 2015) |
| "In the renal cell carcinoma, in contrast with GBM, (13) C multiplets of γ-aminobutyric acid (GABA) differed from its precursor glutamate, suggesting that GABA did not derive from a common glutamate precursor pool." | 1.38 | Glucose metabolism via the pentose phosphate pathway, glycolysis and Krebs cycle in an orthotopic mouse model of human brain tumors. ( Bachoo, RM; Cho, SK; Choi, C; Deberardinis, RJ; Good, LB; Hatanpaa, KJ; Jindal, A; Kapur, P; Maher, EA; Malloy, CR; Marin-Valencia, I; Mashimo, T; Mickey, B; Pascual, JM; Raisanen, J; Rakheja, D; Sun, X; Takahashi, M; Togao, O; Vemireddy, V, 2012) |
| "Renal cell carcinoma is the most lethal of the common urologic malignancies, with no available effective therapeutics." | 1.35 | Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. ( Bharali, DJ; Davis, FB; Davis, PJ; Dyskin, E; Hercbergs, A; Lansing, L; Mousa, SA; Mousa, SS; Yalcin, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 2 (9.09) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 8 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, Z | 1 |
| Tao, W | 1 |
| Guo, X | 1 |
| Jing, C | 1 |
| Zhang, M | 1 |
| Wang, Z | 1 |
| Kong, F | 1 |
| Suo, N | 1 |
| Jiang, S | 1 |
| Wang, H | 1 |
| Guo, T | 1 |
| Zhang, J | 2 |
| Wang, T | 1 |
| Yuan, Z | 1 |
| Tang, H | 1 |
| Zhang, D | 1 |
| Chen, S | 1 |
| Wang, X | 1 |
| Lee, HW | 1 |
| Seo, HS | 1 |
| Yeom, SY | 1 |
| Kim, SN | 1 |
| Kim, CR | 1 |
| Park, DH | 1 |
| Park, W | 1 |
| Choy, YB | 1 |
| Park, CG | 1 |
| Seo, SI | 1 |
| Nizioł, J | 1 |
| Sunner, J | 1 |
| Beech, I | 1 |
| Ossoliński, K | 1 |
| Ossolińska, A | 1 |
| Ossoliński, T | 1 |
| Płaza, A | 1 |
| Ruman, T | 1 |
| Miranda-Gonçalves, V | 1 |
| Lameirinhas, A | 1 |
| Macedo-Silva, C | 1 |
| Lobo, J | 1 |
| C Dias, P | 1 |
| Ferreira, V | 1 |
| Henrique, R | 1 |
| Jerónimo, C | 1 |
| Min, X | 1 |
| Zhang, X | 1 |
| Li, Y | 2 |
| Cao, X | 1 |
| Cheng, H | 1 |
| Li, C | 1 |
| Kong, Q | 1 |
| Mao, Q | 1 |
| Peng, P | 1 |
| Ni, Y | 1 |
| Li, J | 1 |
| Duan, Y | 1 |
| Liu, L | 1 |
| Ding, Z | 1 |
| Ahamed, F | 1 |
| Van Criekinge, M | 3 |
| Wang, ZJ | 4 |
| Kurhanewicz, J | 4 |
| Larson, P | 2 |
| Sriram, R | 4 |
| Huang, J | 1 |
| Zhao, X | 1 |
| Li, X | 1 |
| Peng, J | 1 |
| Yang, W | 1 |
| Mi, S | 1 |
| Xiao, ZD | 1 |
| Han, L | 1 |
| Lee, H | 1 |
| Zhuang, L | 1 |
| Zhang, Y | 1 |
| Baddour, J | 1 |
| Nagrath, D | 1 |
| Wood, CG | 1 |
| Gu, J | 1 |
| Wu, X | 1 |
| Liang, H | 1 |
| Gan, B | 1 |
| Wang, Q | 1 |
| Yan, Y | 1 |
| Guo, P | 1 |
| Xing, Y | 1 |
| Wang, Y | 1 |
| Qin, F | 1 |
| Zeng, Q | 1 |
| Liu, J | 1 |
| Boonkaew, B | 1 |
| Arora, J | 1 |
| Mandava, SH | 1 |
| Maddox, MM | 1 |
| Chava, S | 1 |
| Callaghan, C | 1 |
| He, J | 1 |
| Dash, S | 1 |
| John, VT | 1 |
| Lee, BR | 1 |
| Minton, DR | 1 |
| Fu, L | 1 |
| Chen, Q | 1 |
| Robinson, BD | 1 |
| Gross, SS | 1 |
| Nanus, DM | 1 |
| Gudas, LJ | 1 |
| Leisz, S | 1 |
| Schulz, K | 1 |
| Erb, S | 1 |
| Oefner, P | 1 |
| Dettmer, K | 1 |
| Mougiakakos, D | 1 |
| Wang, E | 1 |
| Marincola, FM | 1 |
| Stehle, F | 1 |
| Seliger, B | 1 |
| Leon Swisher, C | 1 |
| Koelsch, B | 1 |
| Sukumar, S | 1 |
| Santos, RD | 1 |
| Vigneron, D | 1 |
| Hansen, A | 1 |
| Vigneron, DB | 1 |
| Wilson, DM | 2 |
| Keshari, KR | 2 |
| Yalcin, M | 1 |
| Bharali, DJ | 1 |
| Lansing, L | 1 |
| Dyskin, E | 1 |
| Mousa, SS | 1 |
| Hercbergs, A | 1 |
| Davis, FB | 1 |
| Davis, PJ | 1 |
| Mousa, SA | 1 |
| Gerlinger, M | 1 |
| Santos, CR | 1 |
| Spencer-Dene, B | 1 |
| Martinez, P | 1 |
| Endesfelder, D | 1 |
| Burrell, RA | 1 |
| Vetter, M | 1 |
| Jiang, M | 1 |
| Saunders, RE | 1 |
| Kelly, G | 1 |
| Dykema, K | 1 |
| Rioux-Leclercq, N | 1 |
| Stamp, G | 1 |
| Patard, JJ | 1 |
| Larkin, J | 1 |
| Howell, M | 1 |
| Swanton, C | 1 |
| Marin-Valencia, I | 1 |
| Cho, SK | 1 |
| Rakheja, D | 1 |
| Hatanpaa, KJ | 1 |
| Kapur, P | 1 |
| Mashimo, T | 1 |
| Jindal, A | 1 |
| Vemireddy, V | 1 |
| Good, LB | 1 |
| Raisanen, J | 1 |
| Sun, X | 1 |
| Mickey, B | 1 |
| Choi, C | 1 |
| Takahashi, M | 1 |
| Togao, O | 1 |
| Pascual, JM | 1 |
| Deberardinis, RJ | 1 |
| Maher, EA | 1 |
| Malloy, CR | 1 |
| Bachoo, RM | 1 |
| Koelsch, BL | 1 |
| Semenza, GL | 1 |
| Smits, GA | 1 |
| Cornel, EB | 1 |
| van de Boogert, E | 1 |
| Oosterhof, GO | 1 |
| Debruyne, FM | 1 |
| Schalken, JA | 1 |
| Heerschap, A | 1 |
| Chambrier, C | 1 |
| Mercatello, A | 1 |
| Tognet, E | 1 |
| Cottet-Emard, JM | 1 |
| Cohen, R | 1 |
| Blay, JY | 1 |
| Favrot, M | 1 |
| Philip, T | 1 |
| Beylot, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment Development of Triheptanoin for Glucose Transporter Type I Deficiency[NCT02021526] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn (stopped due to NIH funding resulted in new clinical trial) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for lactic acid and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target.
Topics: Apoptosis; Carcinoma, Renal Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell | 2012 |
HIF-1 mediates the Warburg effect in clear cell renal carcinoma.
Topics: Animals; Carcinoma, Renal Cell; Glucose; Glycolysis; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Ind | 2007 |
20 other studies available for lactic acid and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Construction of a Lactate-Related Prognostic Signature for Predicting Prognosis, Tumor Microenvironment, and Immune Response in Kidney Renal Clear Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Female; Humans; Immunity; Kidney; Kidney Neoplasms; Lactic Acid; Male; Progno | 2022 |
Lactic Acid Metabolism and Transporter Related Three Genes Predict the Prognosis of Patients with Clear Cell Renal Cell Carcinoma.
Topics: Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Gene Expression Regulation, Neoplastic; Humans; Ki | 2022 |
Cabozantinib-Loaded PLGA Nanoparticles: A Potential Adjuvant Strategy for Surgically Resected High-Risk Non-Metastatic Renal Cell Carcinoma.
Topics: Animals; Carcinoma, Renal Cell; Drug Carriers; Emulsions; Humans; Kidney Neoplasms; Lactic Acid; Lun | 2022 |
Localization of Metabolites of Human Kidney Tissue with Infrared Laser-Based Selected Reaction Monitoring Mass Spectrometry Imaging and Silver-109 Nanoparticle-Based Surface Assisted Laser Desorption/Ionization Mass Spectrometry Imaging.
Topics: Amino Acids; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lactic Acid; Lasers; Mass Spectrometry | 2020 |
Lactate Increases Renal Cell Carcinoma Aggressiveness through Sirtuin 1-Dependent Epithelial Mesenchymal Transition Axis Regulation.
Topics: Acetylation; Animals; Biological Transport; Cadherins; Carcinoma, Renal Cell; Cell Line, Tumor; Cell | 2020 |
HSPA12A unstabilizes CD147 to inhibit lactate export and migration in human renal cell carcinoma.
Topics: Basigin; Biological Transport; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Prolifer | 2020 |
Modeling hyperpolarized lactate signal dynamics in cells, patient-derived tissue slice cultures and murine models.
Topics: Alginates; Animals; Bioreactors; Carcinoma, Renal Cell; Cell Line, Tumor; Humans; Kidney Neoplasms; | 2021 |
HMGCR inhibition stabilizes the glycolytic enzyme PKM2 to support the growth of renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Carrier Proteins; Cell Line, Tumor; Cell Prol | 2021 |
Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Down-Regulation; Energy Metabolism; Genes, myc; Glucose; HE | 2017 |
RETRACTED: Physcion 8-O-β-glucopyranoside inhibits clear-cell renal cell carcinoma bydownregulating hexokinase II and inhibiting glycolysis.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Down-Regul | 2018 |
Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; | 2015 |
Analyses of the transcriptome and metabolome demonstrate that HIF1α mediates altered tumor metabolism in clear cell renal cell carcinoma.
Topics: Aerobiosis; Animals; Carcinogenesis; Carcinoma, Renal Cell; Gene Expression Profiling; Gene Expressi | 2015 |
Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
Topics: Adenosine Triphosphate; Amino Acids; Carcinoma, Renal Cell; Cell Hypoxia; Cell Line, Tumor; Energy M | 2015 |
Dynamic UltraFast 2D EXchange SpectroscopY (UF-EXSY) of hyperpolarized substrates.
Topics: Alanine; Carcinoma, Renal Cell; Cell Line, Tumor; Enzyme Inhibitors; Enzymes; Humans; Kidney Neoplas | 2015 |
Real-time measurement of hyperpolarized lactate production and efflux as a biomarker of tumor aggressiveness in an MR compatible 3D cell culture bioreactor.
Topics: Biomarkers, Tumor; Bioreactors; Carcinoma, Renal Cell; Cell Line, Tumor; Humans; Hydrogen-Ion Concen | 2015 |
Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.
Topics: Animals; Carcinoma, Renal Cell; Cell Growth Processes; Cell Line, Tumor; Chick Embryo; Chorioallanto | 2009 |
Glucose metabolism via the pentose phosphate pathway, glycolysis and Krebs cycle in an orthotopic mouse model of human brain tumors.
Topics: Animals; Brain Neoplasms; Carcinoma, Renal Cell; Citric Acid Cycle; Disease Models, Animal; gamma-Am | 2012 |
Hyperpolarized 13C-pyruvate magnetic resonance reveals rapid lactate export in metastatic renal cell carcinomas.
Topics: Carbon Isotopes; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Glycolysis; Humans; Kidney Tubu | 2013 |
Effects of high energy shock waves on tumor blood flow and metabolism: 31P/1H/2H nuclear magnetic resonance study.
Topics: Animals; Blood Circulation; Carcinoma, Renal Cell; Deuterium; Energy Metabolism; Humans; Hydrogen-Io | 1994 |
Hormonal and metabolic effects of chronic interleukin-2 infusion in cancer patients.
Topics: Adult; Carcinoma, Renal Cell; Epinephrine; Fatty Acids, Nonesterified; Female; Fever; Glycerol; Huma | 1990 |